Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posaconazole in Toenail Onychomycosis
NCT00491764Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2007
- Primary completion
- Dec 2008
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, single-blind trial of posaconazole in onychomycosis (6 arms), sponsored by Merck & Co. Primary endpoint: Complete Cure of Onychomycosis at 48 weeks. Started Jun 2007; status: completed.
02
Drugs
posaconazole
03
Conditions
onychomycosis
Beyond the preview
Go deeper on NCT00491764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00491764.